

THE DANGERS OF H.R. 3



Some members of Congress are considering a drug pricing plan – H.R. 3 – that could have devastating impacts on American patients, jobs and medical innovation. It relies on a form of price setting in which the U.S. government would determine the value of life-saving medicines based on decisions by foreign governments about which medicines are worth investing in and which ones are not – regardless of what patients and their doctors think.

H.R. 3 THREATENS...

ACCESS

In countries with policies similar to H.R. 3, patients have access to fewer new medicines and wait longer to get the medicines they need. Decisions made by other governments about what medicines and therefore, what patients, are worth has led to discrimination against the elderly, the chronically ill and people with disabilities.

JOBS

The biopharmaceutical industry currently supports more than 4 million U.S. jobs and directly employs more than 800,000 workers in the United States. H.R. 3 could lead to the loss of nearly 1 million of these jobs because of the significant impact it could have on the biopharmaceutical industry in the United States.

INNOVATION

Our collaborative research ecosystem means America leads the world in researching and developing life-saving vaccines and treatments. We cannot take that leadership for granted by implementing policies like H.R. 3, which could reduce new medicines made by small U.S. biotech companies by 90% and eliminate hope for millions of patients.



END THE PANDEMIC AND BUILD A MORE RESILIENT SYSTEM.

We must also prepare for the challenges ahead. To do so, we need more of the innovation and discovery that led to the COVID-19 vaccines and treatments and a stronger scientific delivery system from top to bottom.



MAKE MEDICINES MORE AFFORDABLE.

Every reform must pass a simple test: does it benefit the patient and protect future innovation? We can make medicines more affordable by modernizing Medicare, making insurance work like it should, protecting the safety net by maintaining coverage of medicines for vulnerable patients and fostering a competitive market for medicines.



BUILD A MORE JUST, EQUITABLE HEALTH CARE SYSTEM.

COVID-19 and the disproportionate impact it has had on communities of color has shown us that the time to fix inequities in our health care system is right now. Communities of color must finally receive the highest quality of care. Every patient deserves the opportunity to make rational and informed decisions about their own care.

We can achieve those goals, but the drug pricing plan known as H.R. 3 is not the answer. If implemented, it could have devastating consequences for patients' access to medicines, future innovation and American jobs.